Baseline HCV NS5A Resistance-Associated Variants Do Not Impact SVR12 Rates in Non-Cirrhotic and Post-Liver Transplant Patients With Genotype 1 Infection Treated With Daclatasvir and Sofosbuvir With or Without Ribavirin for 12 Weeks: An Integrated Analysis

Conference Reports for NATAP

66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015


Baseline HCV NS5A Resistance-Associated Variants Do Not Impact SVR12 Rates in Non-Cirrhotic and Post-Liver Transplant Patients With Genotype 1 Infection Treated With Daclatasvir and Sofosbuvir With or Without Ribavirin for 12 Weeks: An Integrated Analysis

	Reported by Jules Levin AASLD 2015 Nov 13-17 San Francisco McPhee F,1 Hernandez D,1 Zhou N,1 Ueland J,1 Vellucci V,1 Hartman-Neumann S,1 Yang X,1 Han Z,1 Yu F,1 Yang R,2 Noviello S2 1Bristol-Myers Squibb Research and Development, Wallingford, CT; 2Bristol-Myers Squibb Research and Development, Princeton, NJ